CA2597707A1 - Systeme de detection d'analyte a detection repartie - Google Patents

Systeme de detection d'analyte a detection repartie Download PDF

Info

Publication number: CA2597707A1
Authority: CA; Canada
Prior art keywords: fluid; sample; passageway; sensor; fluid passageway
Prior art date: 2005-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002597707A

Other languages

English (en)

Inventor

James R. Braig

Kenneth G. Witte

Mark Wechsler

Peter Rule

Richard Keenan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Optiscan Biomedical Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-14

Filing date

2006-02-13

Publication date

2006-08-24

2005-12-21 Priority claimed from US11/316,205 external-priority patent/US20060216209A1/en

2006-02-13 Application filed by Individual filed Critical Individual

2006-08-24 Publication of CA2597707A1 publication Critical patent/CA2597707A1/fr

Status Abandoned legal-status Critical Current

Links

239000012491 analyte Substances 0.000 title claims abstract description 258
238000001514 detection method Methods 0.000 title claims description 199
239000012530 fluid Substances 0.000 claims abstract description 726
238000005070 sampling Methods 0.000 claims abstract description 191
210000001124 body fluid Anatomy 0.000 claims abstract description 123
239000010839 body fluid Substances 0.000 claims abstract description 80
238000000034 method Methods 0.000 claims description 188
238000004458 analytical method Methods 0.000 claims description 153
238000004891 communication Methods 0.000 claims description 59
230000003287 optical effect Effects 0.000 claims description 59
239000003978 infusion fluid Substances 0.000 claims description 26
108010054147 Hemoglobins Proteins 0.000 claims description 22
102000001554 Hemoglobins Human genes 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 17
238000001802 infusion Methods 0.000 claims description 15
238000010790 dilution Methods 0.000 claims description 13
239000012895 dilution Substances 0.000 claims description 13
238000005534 hematocrit Methods 0.000 claims description 12
239000003153 chemical reaction reagent Substances 0.000 claims description 4
230000002255 enzymatic effect Effects 0.000 claims description 2
239000000523 sample Substances 0.000 description 726
238000001228 spectrum Methods 0.000 description 134
239000008280 blood Substances 0.000 description 123
210000004369 blood Anatomy 0.000 description 122
238000005259 measurement Methods 0.000 description 104
239000000463 material Substances 0.000 description 88
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 80
239000008103 glucose Substances 0.000 description 80
239000000306 component Substances 0.000 description 75
210000002381 plasma Anatomy 0.000 description 44
239000007789 gas Substances 0.000 description 39
230000005855 radiation Effects 0.000 description 39
238000010521 absorption reaction Methods 0.000 description 36
239000002699 waste material Substances 0.000 description 31
238000012360 testing method Methods 0.000 description 29
230000003595 spectral effect Effects 0.000 description 28
230000005670 electromagnetic radiation Effects 0.000 description 27
239000007788 liquid Substances 0.000 description 27
229920002307 Dextran Polymers 0.000 description 26
238000002835 absorbance Methods 0.000 description 26
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 25
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 25
229930195725 Mannitol Natural products 0.000 description 25
239000000594 mannitol Substances 0.000 description 25
235000010355 mannitol Nutrition 0.000 description 25
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 25
229960000244 procainamide Drugs 0.000 description 25
230000035945 sensitivity Effects 0.000 description 24
238000002360 preparation method Methods 0.000 description 23
238000002834 transmittance Methods 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
238000000862 absorption spectrum Methods 0.000 description 20
230000008901 benefit Effects 0.000 description 20
239000012528 membrane Substances 0.000 description 18
238000012549 training Methods 0.000 description 18
239000013598 vector Substances 0.000 description 18
238000005086 pumping Methods 0.000 description 14
239000000126 substance Substances 0.000 description 14
239000003814 drug Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
230000008569 process Effects 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
230000005540 biological transmission Effects 0.000 description 12
210000004027 cell Anatomy 0.000 description 12
238000009826 distribution Methods 0.000 description 12
230000002441 reversible effect Effects 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 11
238000004422 calculation algorithm Methods 0.000 description 10
230000008859 change Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
238000012545 processing Methods 0.000 description 10
238000013459 approach Methods 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
230000015654 memory Effects 0.000 description 9
-1 polyethylene Polymers 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000000853 adhesive Substances 0.000 description 8
230000001070 adhesive effect Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
230000007423 decrease Effects 0.000 description 7
210000003743 erythrocyte Anatomy 0.000 description 7
239000010408 film Substances 0.000 description 7
238000011068 loading method Methods 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
239000004033 plastic Substances 0.000 description 7
229920003023 plastic Polymers 0.000 description 7
238000004611 spectroscopical analysis Methods 0.000 description 7
238000011144 upstream manufacturing Methods 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000004698 Polyethylene Substances 0.000 description 6
230000009471 action Effects 0.000 description 6
239000012503 blood component Substances 0.000 description 6
238000011049 filling Methods 0.000 description 6
230000002452 interceptive effect Effects 0.000 description 6
230000002572 peristaltic effect Effects 0.000 description 6
229920000573 polyethylene Polymers 0.000 description 6
238000012546 transfer Methods 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000001276 controlling effect Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
238000004847 absorption spectroscopy Methods 0.000 description 4
230000000712 assembly Effects 0.000 description 4
238000000429 assembly Methods 0.000 description 4
OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 description 4
229910001632 barium fluoride Inorganic materials 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
238000010586 diagram Methods 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
230000004907 flux Effects 0.000 description 4
229910052732 germanium Inorganic materials 0.000 description 4
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
238000004476 mid-IR spectroscopy Methods 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000011002 quantification Methods 0.000 description 4
238000007789 sealing Methods 0.000 description 4
238000000926 separation method Methods 0.000 description 4
239000004696 Poly ether ether ketone Substances 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 3
229910001634 calcium fluoride Inorganic materials 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
210000003722 extracellular fluid Anatomy 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000002483 medication Methods 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000004417 polycarbonate Substances 0.000 description 3
229920002530 polyetherether ketone Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000010703 silicon Substances 0.000 description 3
229910052710 silicon Inorganic materials 0.000 description 3
238000000528 statistical test Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
239000004697 Polyetherimide Substances 0.000 description 2
239000004734 Polyphenylene sulfide Substances 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
235000013405 beer Nutrition 0.000 description 2
239000000560 biocompatible material Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000004590 computer program Methods 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
235000005152 nicotinamide Nutrition 0.000 description 2
239000011570 nicotinamide Substances 0.000 description 2
229960003966 nicotinamide Drugs 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
229920000515 polycarbonate Polymers 0.000 description 2
229920001601 polyetherimide Polymers 0.000 description 2
229920000069 polyphenylene sulfide Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
229960001860 salicylate Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
239000010959 steel Substances 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
229960005371 tolbutamide Drugs 0.000 description 2
229940116269 uric acid Drugs 0.000 description 2
REAWNMHCBIUKLZ-ZYHUDNBSSA-N (3R,4R)-4-(hydroxymethyl)-3-(6-methylheptanoyl)oxolan-2-one Chemical compound CC(C)CCCCC(=O)[C@H]1[C@H](CO)COC1=O REAWNMHCBIUKLZ-ZYHUDNBSSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
208000004434 Calcinosis Diseases 0.000 description 1
108010003320 Carboxyhemoglobin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
108010031093 Deltran Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920004738 ULTEM® Polymers 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000003570 air Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
238000003491 array Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
229960001139 cefazolin Drugs 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
101150071577 chi2 gene Proteins 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
238000000205 computational method Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000007865 diluting Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000002848 electrochemical method Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000005530 etching Methods 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
239000011147 inorganic material Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
238000003754 machining Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
238000002044 microwave spectrum Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000011368 organic material Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229920006289 polycarbonate film Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000012797 qualification Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229910052594 sapphire Inorganic materials 0.000 description 1
239000010980 sapphire Substances 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000004088 simulation Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000012306 spectroscopic technique Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000013179 statistical model Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
239000010409 thin film Substances 0.000 description 1
OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
229960004075 ticarcillin disodium Drugs 0.000 description 1
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
229960002277 tolazamide Drugs 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000007514 turning Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000013022 venting Methods 0.000 description 1
238000001429 visible spectrum Methods 0.000 description 1

Landscapes

Investigating Or Analysing Biological Materials (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Investigating Or Analysing Materials By Optical Means (AREA)

CA002597707A 2005-02-14 2006-02-13 Systeme de detection d'analyte a detection repartie Abandoned CA2597707A1 (fr)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
US65266005P	2005-02-14	2005-02-14
US60/652,660		2005-02-14
US65800105P	2005-03-02	2005-03-02
US60/658,001		2005-03-02
US67355105P	2005-04-21	2005-04-21
US60/673,551		2005-04-21
US72419905P	2005-10-06	2005-10-06
US60/724,199		2005-10-06
US11/316,205 US20060216209A1 (en)	2005-02-14	2005-12-21	Analyte detection system with distributed sensing
US11/316,681		2005-12-21
US11/316,681 US20070082342A1 (en)	2005-02-14	2005-12-21	Near-patient module for analyte detection system
US11/316,205		2005-12-21
PCT/US2006/005005 WO2006088785A1 (fr)	2005-02-14	2006-02-13	Systeme de detection d'analyte a detection repartie

Publications (1)

Publication Number	Publication Date
CA2597707A1 true CA2597707A1 (fr)	2006-08-24

Family

ID=38476258

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002597707A Abandoned CA2597707A1 (fr)	2005-02-14	2006-02-13	Systeme de detection d'analyte a detection repartie

Country Status (4)

Country	Link
EP (1)	EP1850751A1 (fr)
JP (1)	JP2008529676A (fr)
AU (1)	AU2006214516A1 (fr)
CA (1)	CA2597707A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109394240A (zh) *	2018-09-19	2019-03-01	华中科技大学同济医学院附属协和医院	一种具有防凝血功能的新型安全稳定自动采血监控仪

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5758643A (en) *	1996-07-29	1998-06-02	Via Medical Corporation	Method and apparatus for monitoring blood chemistry

2006
- 2006-02-13 JP JP2007555311A patent/JP2008529676A/ja active Pending
- 2006-02-13 AU AU2006214516A patent/AU2006214516A1/en not_active Abandoned
- 2006-02-13 CA CA002597707A patent/CA2597707A1/fr not_active Abandoned
- 2006-02-13 EP EP06734919A patent/EP1850751A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
JP2008529676A (ja)	2008-08-07
EP1850751A1 (fr)	2007-11-07
AU2006214516A1 (en)	2006-08-24
AU2006214516A2 (en)	2006-08-24

Publication	Publication Date	Title
US10568556B2 (en)	2020-02-25	Bodily fluid composition analyzer with disposable cassette
AU2006214523B2 (en)	2011-11-17	Method and apparatus for detection of multiple analytes
US9913604B2 (en)	2018-03-13	Analyte detection systems and methods using multiple measurements
US20060216209A1 (en)	2006-09-28	Analyte detection system with distributed sensing
CA2624302A1 (fr)	2007-04-19	Appareil anticoagulant et procedes de regulation de fluide
CA2624417A1 (fr)	2007-04-19	Systeme et procede d'evaluation des mesures realisees par un dispositif d'analyse de liquide organique
CA2625232A1 (fr)	2007-04-19	Systeme a cassette de manipulation fluidique pour analyseurs de liquides organiques
CA2633561A1 (fr)	2007-06-28	Systeme et procede de detection d'analyte avec prelevement periodique d'echantillon et analyseur de fluide corporel
CA2597610A1 (fr)	2009-08-24	Systeme et procede de detection d'analyte avec un volume d'echantillon reduit
CA2597707A1 (fr)	2006-08-24	Systeme de detection d'analyte a detection repartie

Legal Events

Date	Code	Title	Description
2012-02-13	FZDE	Discontinued